From boardroom to bike – Philip cycles for cancer | Diaceutics

From boardroom to bike – Philip cycles for cancer

May 11th, 2017

For someone who bought his first bike in April, competing in the Prudential Ride London-Surrey 100 race on July 30 2017 is certainly a challenge, but this is the attraction for Philip White, Chief Financial Officer, Diaceutics. Spurred on by the determination to raise funds for a charity very close to his heart, Philip will be following the same route taken by the world’s cycling legends at the London 2012 Olympics. The race, which starts in London and winds through leafy Surrey to the world-famous zig-zags of Box Hill, finishes in spectacular style in front of Buckingham Palace.

Philip will be one of 25,000 cyclists taking part in the iconic race, all of them raising money for their chosen cause. Philip hopes to raise £5,000 for Friends of the Cancer Centre, a Northern Ireland charity supporting the Belfast City Hospital Cancer Centre and local people affected by the disease.

Asked why he had suddenly decided to get on his bike, Philip said, “I’d always wanted to help this charity and felt it was my time to step up. When I saw the race advertised I applied on a whim, really. Then it sunk in – and once you’re signed up, it’s final!”

Philip has taken on a demanding training regime to reach peak performance for the big day. He has joined Phoenix Cycling Club in Belfast for the advice, support and camaraderie, so he’ll not be alone as he pedals through the hundreds of miles of preparation. “My training starts with two 35-mile cycles per week, then increases steadily to 50-mile, 100-mile and eventually 150-mile rides in July, so hopefully the stamina and fitness should build up in good time,” says Philip.

A JustGiving account has been set up for donations and Philip welcomes any support, however small. Donations are already coming in – Diaceutics has pledged £500 and his 8-year-old daughter is a keen fundraiser. “Charlotte can’t wait to start knocking on neighbours’ doors and ask them to sponsor me, and she’s also coming up with ideas to raise money at school. But I have a hunch the newly-installed swear box in the Belfast office might produce the best return on investment.”

Philip adds, “Getting the right diagnostic tests to patients at the right time is a big part of what we do at Diaceutics, so it’s great to be able to help people affected by cancer in another way, through cycling.”

Donations can be made here and all the money raised goes to Friends of the Cancer Centre.

Good luck, Philip, from everyone at Diaceutics.

Webinars & Podcasts

August 20th, 2019
Podcast: How Diaceutics is repairing the diagnostic testing ecoystem for patients worldwide
Diaceutics CEO, Peter Keeling joins Pat Kenny on Newstalk FM to discuss how analyzing Big Data to implement better diagnostic testing can help patients access better treatment options for cancer and other life-threatening diseases.
July 5th, 2019
Liquid Biopsy in NSCLC
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications